最新进展：杂环化合物在药物和药物发现中的应用。
Recent Advances: Heterocycles in Drugs and Drug Discovery.
机构信息
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90128 Palermo, Italy.
出版信息
Int J Mol Sci. 2024 Aug 31;25(17):9503. doi: 10.3390/ijms25179503.
Abstract
Interest and research focusing on the design of novel pharmaceutical agents is always growing [...].
摘要
兴趣和研究集中在新型药物制剂的设计上，这方面的兴趣和研究一直在增长[... ]。
相似文献
1
Recent Advances: Heterocycles in Drugs and Drug Discovery.最新进展：杂环化合物在药物和药物发现中的应用。
Int J Mol Sci. 2024 Aug 31;25(17):9503. doi: 10.3390/ijms25179503.
2
Trends in research of antitrypanosomal agents among synthetic heterocycles.
Eur J Med Chem. 2014 Oct 6;85:51-64. doi: 10.1016/j.ejmech.2014.07.092. Epub 2014 Jul 25.
3
A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery.关于不同杂环化合物作为抗疟药物发现中优势骨架的综述。
Eur J Med Chem. 2018 Oct 5;158:917-936. doi: 10.1016/j.ejmech.2018.08.040. Epub 2018 Aug 19.
4
Modern advances in heterocyclic chemistry in drug discovery.药物研发中杂环化学的现代进展。
Org Biomol Chem. 2016 Jul 12;14(28):6611-37. doi: 10.1039/c6ob00936k.
5
Advancement in chiral heterocycles for the antidiabetic activity.手性杂环在抗糖尿病活性方面的进展。
Chirality. 2024 Feb;36(2):e23637. doi: 10.1002/chir.23637.
6
Overview.概述。
Anticancer Agents Med Chem. 2017;17(1):2.
7
Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization.用于DNA编码文库设计和从苗头化合物到先导化合物优化的特权杂环。
Eur J Med Chem. 2023 Feb 15;248:115079. doi: 10.1016/j.ejmech.2022.115079. Epub 2023 Jan 14.
8
Preface.前言。
Anticancer Agents Med Chem. 2017;17(1):3.
9
Recent advances in the research of heterocyclic compounds as antitubercular agents.杂环化合物作为抗结核药物的研究进展。
ChemMedChem. 2012 Dec;7(12):2063-75. doi: 10.1002/cmdc.201200339. Epub 2012 Oct 5.
10
A Comprehensive Review of N-Heterocycles as Cytotoxic Agents.作为细胞毒性剂的氮杂环化合物综述
Curr Med Chem. 2016;23(38):4338-4394. doi: 10.2174/0929867323666160809093930.
引用本文的文献
1
Benzimidazole-Pyrimidine Hybrids: Synthesis and Medicinal Properties.苯并咪唑 - 嘧啶杂化物：合成与药用特性
Pharmaceuticals (Basel). 2025 Aug 19;18(8):1225. doi: 10.3390/ph18081225.
2
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer's and Parkinson's Diseases.杂环化合物在神经退行性疾病中的治疗作用：来自阿尔茨海默病和帕金森病的见解
Neurol Int. 2025 Feb 7;17(2):26. doi: 10.3390/neurolint17020026.
3
Heterocycles in Medicinal Chemistry II.药物化学中的杂环化合物II。
Molecules. 2024 Oct 11;29(20):4810. doi: 10.3390/molecules29204810.
本文引用的文献
1
Recent advances on anticancer and antimicrobial activities of directly-fluorinated five-membered heterocycles and their benzo-fused systems.直接氟化五元杂环及其苯并稠合体系的抗癌和抗菌活性的最新进展。
RSC Adv. 2024 Jun 19;14(28):19752-19779. doi: 10.1039/d4ra01387e. eCollection 2024 Jun 18.
2
Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application.三唑类化合物在药物化学中的应用：物理化学性质、生物等排体和应用。
J Med Chem. 2024 May 23;67(10):7788-7824. doi: 10.1021/acs.jmedchem.4c00652. Epub 2024 May 3.
3
Synthesis and Antibacterial Activity of Mono- and Bi-Cationic Pyridinium 1,2,4-Oxadiazoles and Triazoles.单阳离子和双阳离子吡啶并[1,2,4]恶二唑和三唑的合成及抗菌活性。
Int J Mol Sci. 2023 Dec 27;25(1):377. doi: 10.3390/ijms25010377.
4
Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis-Pyrazoline Derivatives as Dual EGFR/BRAF Inhibitors.新型双吡唑啉衍生物作为双重 EGFR/BRAF 抑制剂的设计、合成、抗增殖作用及 DFT 研究。
Int J Mol Sci. 2023 May 22;24(10):9104. doi: 10.3390/ijms24109104.
5
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022.2016 年至 2022 年美国食品药品监督管理局批准的含氟杂环药物
Int J Mol Sci. 2023 Apr 23;24(9):7728. doi: 10.3390/ijms24097728.
6
Applications of Bioisosteres in the Design of Biologically Active Compounds.生物等排体在生物活性化合物设计中的应用。
J Agric Food Chem. 2023 Nov 29;71(47):18087-18122. doi: 10.1021/acs.jafc.3c00765. Epub 2023 Mar 24.
7
Benzimidazole Derivatives as New and Selective Inhibitors of Arginase from with Biological Activity against Promastigotes and Amastigotes.苯并咪唑衍生物作为新型和选择性精氨酸酶抑制剂的研究 及其对前鞭毛体和无鞭毛体的生物活性。
Int J Mol Sci. 2021 Dec 19;22(24):13613. doi: 10.3390/ijms222413613.
8
Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs).对抗无意义突变策略：恶二唑类作为翻译通读诱导药物（TRIDs）。
Int J Mol Sci. 2019 Jul 6;20(13):3329. doi: 10.3390/ijms20133329.
Zotero 插件